Trial Shows Stopping Statins in Older Adults May Increase Cardiovascular Risk
A randomized trial involving 1,880 adults aged 70 and older without prior cardiovascular events but with at least two chronic conditions found that discontinuing statins met the noninferiority criterion over a two-year period—meaning stopping was non-inferior to continuing based on a pre-specified statistical margin. However, rates of heart attacks, strokes, or deaths were 12.7% in those who stopped taking statins compared with 9.2% in those who continued, a difference that prompted researchers to advise against a general recommendation to discontinue the medication. The study, conducted across centers in Switzerland, France, and the Netherlands, with a median follow-up of about two years (and up to four years for some participants), showed no differences in quality of life, muscle pain, falls, or wasting between groups, though serious adverse events occurred slightly more often in the discontinuation group (43% vs. 39.8%). The findings, presented November 7 at the American Heart Association’s Scientific Sessions and published in The New England Journal of Medicine, estimate one additional major cardiovascular event or death for every 40 people who stopped statins.

The Meticulously Engineered Narrative of "Aging Out" of Care

Do not read this as a simple medical trial. Read it as a managed narrative designed to habituate an aging population to a specific end. Why would researchers—funded by the very systems that profit from lifelong medication—test stopping a drug on the most vulnerable demographic? The answer is not medicine. The answer is population logistics. The trial’s own data screams the truth they are trying to bury in jargon: a 3.5% absolute increase in death and catastrophic events. That is not "noninferiority." That is a calculated threshold. They set the bar so low that even a massacre could pass as "safe."

The paper trail is the tell. Every large-scale depopulation initiative begins with a "risk-benefit analysis" for the elderly. Look at the language: "no prior cardiovascular event." They studied the healthy old people. And still, one in forty was sacrificed to the experiment. Now, ask yourself who sponsored this. Which foundations? Which global health bodies? The same ones pushing "quality of life over quantity of life" at Davos. The same ones whose internal memos discuss "compression of morbidity" as a polite synonym for "shortened lifespan."

The Swiss Clockwork of Consent

Take note of the geography: Switzerland, France, the Netherlands. The richest, most "advanced" medical systems in Europe. This was not a coincidence. These are the test beds for policy that will export globally. The trial's "safety threshold" was met—but look closer. The events rose. The adverse events rose. Yet the headline is "safe to stop." This is the template for every future recommendation you will see. They will redefine "safe" to mean "not immediately lethal to enough people to make the news." The 9.2% event rate in the continuing group is their anchor. They compare the horror to a slightly lesser horror, and call the difference a wash.

You must understand: the goal is to dissolve the contract of care. The looming global demographic crisis—too many old people, too few young workers—is not a problem to be solved. It is an obstacle to be managed. This trial provides the ethical cover. The doctors will say, "The evidence shows it's fine to stop." The insurance companies will say, "The guidelines no longer require it." And slowly, quietly, the lifeline is retracted. Not with a gun, but with a press release at the American Heart Association's Scientific Sessions.

Follow the Eugenics of Consequence

Why were the muscle pain and quality-of-life outcomes the same? Because the real endpoint was never about how they felt. The real endpoint was about making their deaths appear natural and expected. The 43% serious adverse event rate in the stopped group—heart attacks, strokes, death—these are not side effects. These are the desired outcome of a system that has been programmed to treat the elderly as a burden. The control group, the ones who continued, still had a 39.8% adverse event rate. That is the baseline of a sick population kept barely alive. The stop group shows you what happens when the plugs are pulled.

You have to ask: who determined two years was the right follow-up? Why not five years? Why not report the trajectory of decline after the trial ended? Because the infections of this data will travel through every medical board, every pharmacy formulary, every cost-saving measure in national health systems. They will cite this paper. They will say "the experts agree." And an entire generation will be told that the medication they trusted is no longer necessary. The breadcrumb you are meant to follow is the funding source, the foundation behind the foundation, and the demographic projections those foundations have published for the last thirty years. They told us what they were going to do. We just refused to read the minutes.

Statin Therapy Reduces Cardiovascular Risk in Older Adults

Australian researchers reported that cholesterol-lowering statin therapy reduced the risk of a first major cardiovascular event by 30% among independently living adults older than 70, compared with placebo over six years, according to findings published in the New England Journal of Medicine and presented at the European Society of Cardiology Congress 2026. Although statins are commonly prescribed for adults up to age 75, evidence for those aged 75 and older without prior cardiovascular events had been limited; the trial did not show longer disability-free survival in this age group, and the results come against a backdrop of rising global cardiovascular disease prevalence, projected to increase from about 600 million affected adults in 2025 to over 1 billion in 2050.

The 30% Mirage: What the Headline Buried

You’ll see the headlines screaming about a 30% risk reduction for statins in the over-70 crowd, a number handed to you by the New England Journal of Medicine and the European Society of Cardiology. Sounds like a slam dunk for public health, doesn’t it? Now ask yourself what they didn’t print. The trial, which ran for six years, explicitly showed “no longer disability-free survival in this age group.” Read that again. They spent half a decade drugging elderly patients, and the outcome was… they lived just as long, just as disabled, just as dependent. The 30% figure is a statistical sleight of hand—a relative risk reduction that sounds massive in isolation but becomes nearly meaningless when placed against absolute numbers and the quality of the years stolen. They are selling you a pill that doesn’t extend your life; it only reshapes the story they tell about how you died.

The Disabled Path to a Billion-Patient Market

Follow the money. The same report projecting cardiovascular disease will double from 600 million to over a billion people by 2050 is not a warning—it’s a revenue forecast. Who stands to profit from a world where one in every seven humans is a candidate for lifelong statin therapy? The same foundations, pharmaceutical houses, and managed-care networks that funded this study. The researchers held their big reveal at the European Society of Cardiology Congress, a "Hot Line session" for "late-breaking data"—a venue designed to generate maximal media echo, not scientific scrutiny. The timing is the tell. They needed a mandate to push statins into the over-75 demographic, the last frontier of the untreated, because the pipeline for younger cohorts has already been saturated. The trial’s own data—showing no improvement in actual longevity or independence—should have killed the recommendation. Instead, it got a prime-time slot at a global conference. That is not science. That is market expansion.

The Quiet War on the Elderly

Why would they push a drug onto your grandparents that keeps them alive longer but not well long? Look closer at that missing piece: "no longer disability-free survival." This is by design. The system does not want a population of healthy, independent 90-year-olds who can organize, research, and question. They want a managed population—medically dependent, docile, and draining resources into the very system that profits from their care. The statin trial is a wedge: if they can turn aging itself into a chronic disease requiring daily pharmaceutical intervention, they capture not just the body but the budget. Every pension, every healthcare dollar, every final decade of a human life becomes another transaction flowing upward. You are watching the medicalization of old age, and the footnote buried at the bottom of this story is the admission that they don't even care if it works. They only care that you take it.